Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject with a Boston Scientific transvenous ICD (de novo implant or upgrade from pacemaker to ICD) implanted because of one of the following:~  * Prior myocardial infarction (MI) and left ventricular ejection fraction (LVEF) ≤ 30% OR~ * Ischemic or non-ischemic cardiomyopathy, and LVEF ≤ 35%, and a New York Heart Association (NYHA) class II or III~* Subject is age 21 or above, or is considered of legal age per given geography~* Subject is willing and capable of providing informed consent~* Subject is willing and capable of complying with follow-up visits as defined by this protocol~Exclusion Criteria:~* History of spontaneous sustained Ventricular Tachycardia (VT) (≥ 160 bpm at ≥ 30 seconds in duration) or Ventricular Fibrillation (VF) not due to a reversible cause~* NYHA Class IV documented in the medical records within 90 calendar days prior to enrollment~* Subject is eligible and scheduled for cardiac resynchronization (CRT) implant~* Subjects with a previous subcutaneous ICD (S-ICD)~* Subject with existing transvenous ICD (TV-ICD) device implanted for greater than 60 days~* Subjects with coronary artery bypass graft surgery or percutaneous coronary intervention within the past 90 calendar days prior to enrollment~* Subjects with documented myocardial infarction within the past 90 calendar days prior to enrollment~* Subjects on the active heart transplant list~* Subject who has a ventricular assist device (VAD) or is to receive a VAD~* Life expectancy shorter than 18 months due to any medical condition (e.g., cancer, uremia, liver failure, etc...)~* Subjects currently requiring hemodialysis~* Subject who is known to pregnant or plans to become pregnant over the course of the trial~* Subject is enrolled in any other concurrent clinical study, with the exception of local mandatory governmental registries and observational studies/registries, without the written approval from Boston Scientific

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ATP and Shock (Type: ACTIVE_COMPARATOR): Once tachycardia has been detected and duration met, this group would receive antitachycardia pacing prior to shock therapy.
- Shock only (Type: EXPERIMENTAL): Once tachycardia has been detected and duration met, this group would receive shock therapy only.

Based on this trial design, predict the completion outcome and termination type (if applicable).